LEXINGTON, Mass., Nov. 7, 2017 /PRNewswire/ -- Aldeyra
Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra" or "the
Company"), a clinical-stage biotechnology company devoted to
treating inflammation, inborn errors of metabolism, and other
diseases related to endogenous aldehyde toxicity, today announced
that Todd C. Brady, M.D., Ph.D.,
President and CEO of Aldeyra, will present and host one-on-one
meetings at the Stifel 2017 Healthcare Conference on Tuesday, November 14, 2017.
Event: The Stifel 2017 Healthcare Conference
Date: Tuesday, November 14,
2017
Time: 5:00 PM ET
Location: The Lotte New York Palace Hotel in New York City
About Aldeyra
Therapeutics
Aldeyra Therapeutics, Inc. is a
biotechnology company devoted to improving lives by inventing,
developing and commercializing products that treat diseases thought
to be related to endogenous aldehydes, a naturally occurring class
of pro-inflammatory and toxic molecules. Aldeyra's lead
product candidate, ADX-102, is an aldehyde trap in development as
topical eye drops for the treatment of ocular inflammation. ADX-102
has now been tested in over 250 patients in Phase 2 clinical trials
in dry eye disease, allergic conjunctivitis, and noninfectious
anterior uveitis. A dermatologic formulation of ADX-102 is in
late-stage clinical development for the treatment of ichthyosis due
to Sjögren-Larsson Syndrome, an inborn error of aldehyde
metabolism. ADX-102 has not been approved for sale in the U.S. or
elsewhere.
Corporate Contact:
Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 205
stulipano@aldeyra.com
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Chris.brinzey@westwicke.com
Media Contact:
Cammy Duong
MacDougall Biomedical Communications
Tel: 781-591-3443
cduong@macbiocom.com
View original
content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-to-present-at-the-stifel-2017-healthcare-conference-300550338.html
SOURCE Aldeyra Therapeutics, Inc.